Showing posts with label ACE inhibitors. Show all posts
Showing posts with label ACE inhibitors. Show all posts

Monday, November 5, 2018

Common Blood Pressure Drugs Tied to Increased Lung Cancer Risk

Angiotensin-converting-enzyme (ACE) inhibitors are associated with increased lung cancer risk compared with angiotensin-receptor blockers (ARBs), an observational study in The BMJ suggests.

Using a U.K. primary care database, researchers identified over 900,000 adults who began treatment with a new antihypertensive drug class from 1995 through 2015. Those with histories of cancer were excluded.

During a mean 6 years' follow-up, lung cancer was diagnosed in 0.8% of the cohort. After adjustment for smoking and other confounders, ACE inhibitor use was associated with significantly increased lung cancer risk relative to ARB use (1.6 vs. 1.2 per 1000 person-years). The increased risk didn't appear until after 5 years of ACE inhibitor use, and then increased with increasing duration of use.

The authors note that ACE inhibitors lead to accumulation of bradykinin in the lungs, which "may directly stimulate growth of lung cancer." An editorialist, meanwhile, concludes, "In an individual patient, concerns about the long term risk of lung cancer should be balanced against gains in life expectancy associated with use of [ACE inhibitors]."

My Take:
ACE inhibitors are one of the three antihypertensive medications I mentioned in last Friday’s blog. Remember that I also mentioned that these drugs cause fluid retention in the lungs and legs (congestive heart failure). Bradykinin is a peptide produced in the kidneys that causes vasodilatation thus lowering blood pressure. When the body is in homeostasis, bradykinin is short lived. However, ACE inhibitors cause this peptide to build up in the lungs, along with the edema, where it acts as a carcinogen.

Friday, April 20, 2018

Time to Ditch ACE Inhibitors for CVD?

There is “little, if any, clinical reason” to use angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension or other cardiovascular indications because angiotensin receptor blockers (ARBs) are just as effective with fewer side effects, a new review concludes.

The review, published in the Journal of the American College of Cardiology on April 3, was led by Franz Messerli, MD, University Hospital, Bern Switzerland.

Messerli and colleagues reviewed data from 119 randomized clinical trials of ACE inhibitors and ARBs in more than half a million patients and found no difference in efficacy between the two drug classes with regard to the surrogate endpoint of blood pressure and the outcomes of all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. But ACE inhibitors have a higher incidence of adverse reaction – namely cough and very low risks of angioedema and fatalities – that are more prevalent in dark-skinned people, they write.

Despite this, most guidelines for the management of patients with cardiovascular disease recommend ACE inhibitors as first-choice therapy, whereas ARBs are merely considered an alternative for ACE inhibitor-intolerant patients, Messerli and colleagues point out.

My Take:
The rest of the article is rebuttal from various cardiologists on the pros and cons of using ARBs in lieu of ACE. The best quote – “And the side effect of angioedema, although rare, can be fatal, and if ACE inhibitors are proposed as part of the polypill then millions will be exposed and fatalities will occur.”